Patents by Inventor Noriaki Endo

Noriaki Endo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220411959
    Abstract: The present invention relates to a susceptor including a substrate including a carbon material and having one main surface on which a silicon water is to be placed, and another main surface facing the one main surface, in which an entire surface of the substrate is covered with a thin film including silicon carbide, the one main surface has an emissivity variation of 3% or less, and a ratio of an average emissivity between the one main surface and the another main surface facing the one main surface is from 1:1 to 1:0.8.
    Type: Application
    Filed: June 13, 2022
    Publication date: December 29, 2022
    Inventors: Akira KANNO, Noriaki ENDO, Takahiro TABEI, Masatoshi INOUE
  • Patent number: 6686353
    Abstract: Cyclic diamines of formula (I) or their pharmacologically acceptable acid addition salts, and their medical applications are described. These compounds inhibit the action of chemokines such as MIP-1a and/or MCP-1 on target cells, and are useful as a therapeutic drug and/or preventative drug in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissue.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: February 3, 2004
    Assignees: Teijin Intellectual Property Center Limited, Combichem, Inc.
    Inventors: Tatsuki Shiota, Shinsuke Yamagami, Kenichiro Kataoka, Noriaki Endo, Hiroko Tanaka, Doug Barnum, Jonathan Greene, Wilna Moree, Michele Ramirez Weinhouse, Christine M. Tarby
  • Patent number: 6451842
    Abstract: A compound represented by the general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, and their medical applications. These compounds inhibit the action of chemokines such as MIP-1&agr; and/or MCP-1 on target cells, and are useful as therapeutic and/or preventative drugs in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.
    Type: Grant
    Filed: May 16, 2000
    Date of Patent: September 17, 2002
    Assignees: Dupont Pharmaceuticals Company, Teijin Limited
    Inventors: Tatsuki Shiota, Ken-ichiro Kataoka, Minoru Imai, Takaharu Tsutsumi, Masaki Sudoh, Ryo Sogawa, Takuya Morita, Takahiko Hada, Yumiko Muroga, Osami Takenouchi, Minoru Furuya, Noriaki Endo, Christine M. Tarby, Wilna Moree, Steven Teig
  • Patent number: 6410566
    Abstract: A compound represented by the general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, and their medical applications. These compounds inhibit the action of chemokines such as MIP-1&agr; and/or MCP-1 on target cells, and are useful as therapeutic and/or preventative drugs in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: June 25, 2002
    Assignees: Teijin Limited, Dupont Phamaceuticals Company
    Inventors: Tatsuki Shiota, Ken-ichiro Kataoka, Minoru Imai, Takaharu Tsutsumi, Masaki Sudoh, Ryo Sogawa, Takuya Morita, Takahiko Hada, Yumiko Muroga, Osami Takenouchi, Minoru Furuya, Noriaki Endo, Christine M. Tarby, Wilna Moree, Steven Teig
  • Patent number: 6362177
    Abstract: A compound represented by the general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, and their medical applications. These compounds inhibit the action of chemokines such as MIP-1&agr; and/or MCP-1 on target cells, and are useful as therapeutic and/or preventative drugs in diseases, such as atheroclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: March 26, 2002
    Assignees: Teijin Limited, Dupont Pharmaceuticals Research Laboratories
    Inventors: Tatsuki Shiota, Ken-ichiro Kataoka, Minoru Imai, Takaharu Tsutsumi, Masaki Sudoh, Ryo Sogawa, Takuya Morita, Takahiko Hada, Yumiko Muroga, Osami Takenouchi, Minoru Furuya, Noriaki Endo, Christine M. Tarby, Wilna Moree, Steven Teig
  • Patent number: 5990346
    Abstract: A prostaglandin having formula (I), (II), or (III): ##STR1## a process of production thereof, and inhibitors of cell migration caused by chemokines containing (I) or (II) as an active ingredient.
    Type: Grant
    Filed: February 26, 1997
    Date of Patent: November 23, 1999
    Assignee: Teijin Limited
    Inventors: Kenichiro Kataoka, Toru Minoshima, Tatsuki Shiota, Takaharu Tsutsumi, Takahiko Hada, Hiroko Tanaka, Takuya Morita, Noriaki Endo
  • Patent number: 5731452
    Abstract: 7-thiaprostaglandins having the formula (I) which inhibit cell migration induced by monocyte chemoattractant protein MCP-1/MCAF and other chemokines and can serve as drugs for the treatment of atherosclerosis, diabetic angiopathy, and other disorders, their enantiomers, mixtures of the same, and methods of production thereof.
    Type: Grant
    Filed: September 18, 1995
    Date of Patent: March 24, 1998
    Assignee: Teijin Limited
    Inventors: Toru Minoshima, Kenichiro Kataoka, Hiroko Tanaka, Koji Ishii, Noriaki Endo
  • Patent number: 5106955
    Abstract: A process for production of antibody conjugates which comprises modification of a part of the amino groups in an antibody or its fragment whose antigen-binding activity is lowered by the modification of its amino groups, with a reversible modifier for protein amino groups, reaction of the antibody or its fragment with a substance bearing a group reactive with the amino group and removal of the residues of the reversible modifier from the amino groups and, when necessary, the residues of the substance bearing a group reactive with the amino group in case they are introduced onto groups other than amino groups. The process according to the present invention gives antibody conjugates with retention of antigen-binding activity and these conjugates have a possibility of being used in affinity chromatography or as a diagnostic agent or a drug for cancer therapy.
    Type: Grant
    Filed: November 23, 1988
    Date of Patent: April 21, 1992
    Assignee: Teijin Limited
    Inventors: Noriaki Endo, Yumiko Takeda, Yoshinori Kato, Takeshi Hara
  • Patent number: 4567897
    Abstract: In a digital scan converter, a vector data generator is provided. When the scanning mode is selected, the predetermined vector data adapted to the selected scanning mode is generated from the vector data generator. This vector data is temporarily stored and then used when the actual scanning commences.
    Type: Grant
    Filed: August 16, 1984
    Date of Patent: February 4, 1986
    Assignee: Kabushiki Kaisha Toshiba
    Inventors: Noriaki Endo, Tsuyoshi Yoshie